Supernus Pharmaceuticals is a specialty pharmaceutical company engaged in the development and commercialization of products for treating central nervous system (CNS) diseases. The company is in the process of developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD, including ADHD patients who have impulsive aggression. Product candidates include Trokendi XR and SPN-804 for epilepsy, SPN-810 for impulsive aggression in ADHD, and SPN-812 for ADHD. For more information, visit the company’s Web site at www.supernus.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: